Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Dyne Therapeutics, Inc. | dyn-10k_20201231.htm |
| EX-32.2 - EX-32.2 - Dyne Therapeutics, Inc. | dyn-ex322_6.htm |
| EX-32.1 - EX-32.1 - Dyne Therapeutics, Inc. | dyn-ex321_7.htm |
| EX-31.2 - EX-31.2 - Dyne Therapeutics, Inc. | dyn-ex312_8.htm |
| EX-31.1 - EX-31.1 - Dyne Therapeutics, Inc. | dyn-ex311_9.htm |
| EX-21.1 - EX-21.1 - Dyne Therapeutics, Inc. | dyn-ex211_146.htm |
| EX-10.21 - EX-10.21 - Dyne Therapeutics, Inc. | dyn-ex1021_147.htm |
| EX-4.3 - EX-4.3 - Dyne Therapeutics, Inc. | dyn-ex43_148.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-248873 on Form S-8 of our report dated March 4, 2021, relating to the financial statements of Dyne Therapeutics, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 4, 2021